Literature DB >> 3257410

Expression of the human T-cell-specific tyrosine kinase YT16 (lck) message in leukemic T-cell lines.

Y Koga1, N Kimura, J Minowada, T W Mak.   

Abstract

To evaluate the role of the human T-cell-specific tyrosine kinase lck (YT16), we measured the levels of lck expression in thymocytes, peripheral T-cells, and leukemia T-cell lines which are arrested at different stages of thymic differentiation. The results indicate that higher levels of the lck message can be found in total thymocytes and T-cells arrested at Stage III (thymocytes that have rearranged their alpha, beta, and gamma chain T-cell receptor genes). A 20-fold lower level of these transcripts, however, can be found in cells derived from Stage I cells (thymocytes with germline alpha, beta, and gamma genes), 4 times less messages in Stage II cells (thymocytes with rearranged gamma and beta chain genes, but with germline alpha chain genes), and a 4-fold lower amount of RNA in Stage IV cells (mature lymphocytes). Culture of these cells with a variety of inducing reagents indicated that leukemia cell lines of only Stages I and II can be induced to increase their levels of YT16 expression by the addition of tetradecanoyl phorbol-13-acetate. These results suggest that there may be a developmental regulation of these tyrosine kinase messages during T-cell ontogeny. The high level of these transcripts in more mature T-cell leukemia lines suggests that they may primarily play a role in the proliferative controls of these cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40tax.

Authors:  F Uchiumi; K Semba; Y Yamanashi; J Fujisawa; M Yoshida; K Inoue; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

2.  Creation and characterization of temperature-sensitive mutants of the lck tyrosine protein kinase.

Authors:  T R Hurley; K E Amrein; B M Sefton
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.

Authors:  L B Vogel; D J Fujita
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

4.  Structure of the two promoters of the human lck gene: differential accumulation of two classes of lck transcripts in T cells.

Authors:  T Takadera; S Leung; A Gernone; Y Koga; Y Takihara; N G Miyamoto; T W Mak
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 5.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Changes in the relative abundance of type I and type II lck mRNA transcripts suggest differential promoter usage during T-cell development.

Authors:  P J Reynolds; J Lesley; J Trotter; R Schulte; R Hyman; B M Sefton
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

7.  Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.

Authors:  H T Adler; P J Reynolds; C M Kelley; B M Sefton
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation.

Authors:  A Veillette; I D Horak; E M Horak; M A Bookman; J B Bolen
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

9.  Lymphocyte-Specific Protein Tyrosine Kinase (LCK) is Involved in the Aryl Hydrocarbon Receptor-Mediated Impairment of Immunoglobulin Secretion in Human Primary B Cells.

Authors:  Jiajun Zhou; Qiang Zhang; Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2018-10-01       Impact factor: 4.849

10.  Developmental regulation of lck gene expression in T lymphocytes.

Authors:  R S Wildin; A M Garvin; S Pawar; D B Lewis; K M Abraham; K A Forbush; S F Ziegler; J M Allen; R M Perlmutter
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.